The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021
Open accessAbstract
Background Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We measured seroconversion and seroprevalence of type 2 polio antibodies in children who were reported to have received two doses of nOPV2 in outbreak response campaigns. Methods In this community serosurvey, children born after Jan 1, 2016 were enrolled from seven districts in Tajikistan. Dried blood spot cards were collected before nOPV2 campaigns and after the first and second rounds of the campaigns and were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) for microneutralisation assay to determine presence of polio antibodies. The primary endpoint was to assess change in seroprevalence and seroconversion against poliovirus serotype 2 after one and two doses of nOPV2. Findings 228 (97%) of 236 enrolled children were included in the analysis. The type 2 antibody seroprevalence was 26% (53/204; 95% CI 20 to 33) before nOPV2, 77% (161/210; 70 to 82) after one dose of nOPV2, and 83% (174/209; 77 to 88) after two doses of nOPV2. The increase in seroprevalence was statistically significant between baseline and after one nOPV2 dose (51 percentage points [42 to 59], p<0·0001), but not between the first and second doses (6 percentage points [–2 to 15], p=0·12). Seroconversion from the first nOPV2 dose, 67% (89/132; 59 to 75), was significantly greater than that from the second nOPV2 dose, 44% (20/45; 30 to 60; χ 2 p=0·010). Total seroconversion after two nOPV2 doses was 77% (101/132; 68 to 83). Interpretation Our study demonstrated strong immune responses following nOPV2 outbreak response campaigns in Tajikistan. Our results support previous clinical trial data on the generation of poliovirus type 2 immunity by nOPV2 and provide evidence that nOPV2 can be appropriate for the cVDPV2 outbreak response. The licensure and WHO prequalification of nOPV2 should be accelerated to facilitate wider use of the vaccine. Funding World Health Organization, Centers for Disease Control and Prevention, and Rotary International.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nOPV2 is effective in inducing an immune response in children and can be used to eliminate WPV2 transmission, according to a study conducted in Tajikistan in 2021 [125].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [125]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication
Minor, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.071 · Cited by 183
Macklin, G., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Krishnan, R. S. G., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 156
Self-citationBurns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153
Van Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Priming after a Fractional Dose of Inactivated Poliovirus Vaccine
Resik, S., Tejeda, A., Sutter, R. W., Dı́az, M., Sarmiento, L., Alemañy, N., Garcia, G., Fonseca, M. C., Hung, L. H., Kahn, A.-L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1202541 · Cited by 139
Standardized Methods for Detection of Poliovirus Antibodies
Weldon, W. C., Oberste, M. S., & Pallansch, M. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3292-4_8 · Cited by 128
Anand, A., Zaman, K., Estívariz, C. F., Yunus, M., Gary, H. E., Weldon, W. C., Bari, T. I. A., Oberste, M. S., Wassilak, S. G. F., Luby, S. P., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.039 · Cited by 106
Cited by
Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
Yeh, M. T., Smith, M. R., Carlyle, S., Konopka‐Anstadt, J. L., Burns, C. C., Konz, J., Andino, R., & Macadam, A. J. (2023) · Nature · doi:10.1038/s41586-023-06212-3 · Cited by 66
The Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
Use of inactivated poliovirus vaccine for poliovirus outbreak response
Bandyopadhyay, A. S., Cavestany, R. L., Blake, I. M., Macklin, G., Cooper, L., Grassly, N. C., Nery, A. L. M. D. S., & Mach, O. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00505-4 · Cited by 29
Self-citationMohanty, A., Rohilla, R., Zaman, K., Hada, V., Dhakal, S., Shah, A., Padhi, B. K., Al‐qaim, Z. H., Altawfiq, K. J. A., Tirupathi, R., et al. (2023) · Infezioni in Medicina · doi:10.53854/liim-3102-5 · Cited by 27
Cooper, L., Erbeto, T. B., Danzomo, A. A., Abdullahi, H., Boateng, K., Adamu, U. S., Shuaib, F. M. B., Ndoutabé, M., Gray, E. J., Bandyopadhyay, A. S., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00688-6 · Cited by 27
Metadata
- Authors
- Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., & Mach, O.
- Affiliations
- World Health Organization (CH)
- Centers for Disease Control and Prevention (US)
- World Health Organization Regional Office for Europe (DK)
- Corresponding author
- Macklin, Grace R
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 10
- Issue
- 12
- Pages
- e1807-e1814
- ISSN
- 2214-109X (ISSN-L)
- PMC
- PMC9681660
- OpenAlex
- W4309107156
- Cited by
- 30
- References
- 25
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 1
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/3.0/igo/ (vor)
- Locations
- The Lancet Global Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- World Health Organization
- Rotary Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliovirus type 2, seroconversion, seroprevalence, polio vaccination campaigns, outbreak response, circulating vaccine-derived poliovirus, Tajikistan, children, dried blood spots, polio eradication, vaccine immunogenicity
- MeSH terms
- Antibodies, Viral, Child, Humans, Poliomyelitis, Poliovirus Vaccine, Oral, Tajikistan, Seroepidemiologic Studies, Immunization Programs, Poliovirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. https://app.cochat.ai/papers/10.1016/s2214-109x(22)00412-0
- The paper
- Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., & Mach, O. (2022). Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(22)00412-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.